Recognition and management of chronic nociplastic pain is crucial in rheumatology, with research indicating patients suffering from RA, PsA, and AxSpA experience inadequate response to standard therapies when central sensitization is present. Defined as a new pain category by the IASP, nociplastic pain is frequently seen alongside conditions like fibromyalgia. Despite their significance, rheumatologists often find themselves untrained and under-resourced to address the complexities of this pain type, which can severely impact patient outcomes if ignored. Experts highlight the critical nature of acknowledging and treating nociplastic pain to improve overall patient care.
I assume that 20%-25% of our patients, with whatever disease they have, have pain that isn't driven by inflammation. If you ignore that, you do so at your peril.
Chronic nociplastic pain, characterized by central sensitization, requires specialized attention in rheumatology, as standard therapies may be ineffective.
Collection
[
|
...
]